Trials / Completed
CompletedNCT04827160
Prediction of Thrombosis Using D-dimer Trends in COVID-19
Predictive Value of D-dimers Trends and Levels for Thrombosis in Patients With COVID-19
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 280 (actual)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A high incidence of venous thromboembolic events (VTE) has been demonstrated in COVID-19. This incidence correlates with disease severity. Activation of coagulation secondary to sepsis combined with classical thrombotic risk factors may contribute to this prothrombotic state. Since the beginning of March 2020, the issue of venous thrombosis during SARS-CoV-2 infection has rapidly emerged as a major medical challenge since a significant rate of patients were thrombosing, some of them in spite of a well conducted preventive anticoagulation. Although D-dimers have been shown to be useful in identifying patients at risk of severe COVID-19 and even mortality, they cannot be used for diagnostic exclusion of pulmonary embolism. Indeed, since D-dimer levels rise non-specifically during infectious states, the exclusion threshold of 500 ng/ml cannot be used. It would therefore be useful to study the predictive value of D-dimers for thrombosis in COVID-19 patients.
Detailed description
Primary outcome : Characterize different D-dimer trends in COVID-19 patients. Secondary outcomes : * Identify the predictive value of different D-dimers trends for thrombosis / all-cause mortality / orotracheal intubation during hospitalization * Identify the predictive value of D-dimers at admission for thrombosis / all-cause mortality / orotracheal intubation during hospitalization * Identify the predictive value of 1st D-dimer/fibrinogen ratio for thrombosis / all-cause mortality / orotracheal intubation during hospitalization
Conditions
Timeline
- Start date
- 2020-03-02
- Primary completion
- 2020-08-11
- Completion
- 2020-08-11
- First posted
- 2021-04-01
- Last updated
- 2021-04-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04827160. Inclusion in this directory is not an endorsement.